Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is expected to see opportunities in both the Greenfield and Brownfield categories, as many capped or limited fertility programs leave employees underserved. Additionally, the company's active management of a selective network of high-quality providers gives it a competitive edge. The recent quarterly results and management's guidance show strong performance and momentum, with potential for margin expansion driven by operating leverage.

Bears say

Progyny is currently facing concerns around potential shifts in market share and a reliance on market share gains rather than Greenfield opportunities, as well as potential impacts from the TrumpRx healthcare plan. While the company has a large and growing market opportunity and has seen consistent client retention and interest, there are lingering fears about unemployment affecting results and potential challenges in the upcoming selling season. Additionally, the company's guidance continues to assume conservative levels of utilization and consumption, potentially signaling a slower growth trajectory. As a result, caution is advised in investing in Progyny's stock.

Progyny (PGNY) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 10 analysts, Progyny (PGNY) has a Buy consensus rating as of Jun 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.